Efficacy and safety of a combined Porcine Circovirus and Mycoplasma hyopneumoniae vaccine in finishing pigs

Witvliet, M.; Holtslag, H.; Nell, T.; Segers, R. P. A. M.; Fachinger, Vicky

doi:10.1016/j.trivac.2015.04.002

Cited by 12 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This historical comparison of productivity data for 20 nursery and 23 finishing herds following initiation of Porcilis® PCV M Hyo vaccination demonstrated a significant improvement in average daily weight gain amounting to 34 g in finishing herds, confirming previous findings in randomized, controlled trials [ 1 – 5 ]. In addition, a significant reduction in mortality of 0.4–0.5 percentage points was found both in nursery and finishing herds.…”

Section: Discussionsupporting

confidence: 85%

“…Some randomized, parallel-group field studies have also demonstrated superiority of Porcilis® PCV M Hyo compared to other PCV2 + M. hyopneumoniae vaccines concerning significantly reduced enzootic pneumonia-like lung lesions [ 3 , 4 ] and PCV2 viremia [ 3 ]. No significant effect on mortality has been found in any of these studies, which could be speculated to be partly due to the PCV2 infections being subclinical (as in [ 1 – 5 ]) and partly due to the parallel study design allowing non-vaccinated pigs to benefit from vaccinated pigs (in terms of infectious pressure) and vice versa due to commingling [ 6 ] Usually, all pigs in a herd are either vaccinated or not, and individual-herd vaccine effect-evaluation is primarily based on whether the routinely generated herd productivity reports show improvements in mortality, average daily weight gain and/or feed conversion rate following implementation of a vaccination strategy. Although such a historical comparison has the obvious confounding effect of time, the impact of vaccination on i.e.…”

Section: Introductionmentioning

confidence: 98%

“…Since the safety and efficacy of Porcilis® PCV M Hyo 1 against the combined infection with Porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae ( M. hyopneumoniae ) was first described [ 1 ], the vaccine has been used widely. Later studies in individual herds with a parallel-group study design have demonstrated improved average daily weight gain of 30–50 g and reduced enzootic pneumonia-like lung lesions compared to non-vaccinated controls [ 1 – 3 ]. Some randomized, parallel-group field studies have also demonstrated superiority of Porcilis® PCV M Hyo compared to other PCV2 + M. hyopneumoniae vaccines concerning significantly reduced enzootic pneumonia-like lung lesions [ 3 , 4 ] and PCV2 viremia [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Field evaluation of a ready-to-use combined Porcine circovirus type 2 and Mycoplasma hyopneumoniae vaccine in Denmark – a historical comparison of productivity parameters in 20 nursery and 23 finishing herds

Nielsen¹,

Haugegaard²,

Jolie³

2018

Porc Health Manag

View full text Add to dashboard Cite

BackgroundIn practice, field evaluation of vaccine efficacy in individual herds is often based on a historical comparison of productivity data following initiation of vaccination. Being biased by time, this study design highly contrasts the more controlled, parallel-group design used for most initial vaccine efficacy studies but offers the possibility of including a larger number of animals and herds. As an important add-on to previous findings in controlled studies, the objective of this study was to evaluate the field efficacy of the ready-to-use combination vaccine Porcilis® PCV M Hyo (MSD Animal Health) by an observational historical study design using routinely generated herd productivity data.ResultsData on mortality, average daily weight gain and feed conversion rate were collected as yearly averages for one year prior to and one year after implementation of Porcilis® PCV M Hyo vaccination from 20 nursery and 23 finishing herds. When comparing pre- and post-vaccination periods, the average improvements in productivity data amounted to − 0.4 percentage points for mortality (p = 0.014), + 5 g for average daily weight gain (p = 0.555) and − 0.06 feeding units(FU)/kg for feed conversion rate (p = 0.074) in nursery herds and − 0.5 percentage points for mortality (p = 0.012), + 34 g for average daily weight gain (p < 0.001) and − 0.04 FU/kg for feed conversion rate (p = 0.133) in finishing herds. Even though some nursery and finishing herds also previously vaccinated against PCV2 and/or Mycoplasma hyopneumoniae, this did not significantly affect the results. For finishers, these results were obtained when difference in arrival weights between the periods and shared ownership of the herds were additionally taken into account.ConclusionIn these 20 nursery and 23 finishing herds, previous findings from parallel-group vaccination studies concerning average daily weight gain for finishers were confirmed. Additionally, a significant effect on mortality for both nursery and finishing herds was demonstrated in this evaluation based on routinely generated herd productivity data.Electronic supplementary materialThe online version of this article (10.1186/s40813-018-0104-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Field evaluation of a ready-to-use combined Porcine circovirus type 2 and Mycoplasma hyopneumoniae vaccine in Denmark – a historical comparison of productivity parameters in 20 nursery and 23 finishing herds

Nielsen¹,

Haugegaard²,

Jolie³

2018

Porc Health Manag

View full text Add to dashboard Cite

show abstract

“…The PCV2 viral load was determined by the Boxmeer MSD R&D Service Laboratory by a PCV2-specific real-time polymerase chain reaction [ 20 ].…”

Section: Assessment Of Vaccine Safety and Efficacymentioning

confidence: 99%

A field efficacy and safety trial in the Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use porcine circovirus type 2 and Mycoplasma hyopneumoniae combined vaccine

Kaalberg¹,

Geurts

Jolie³

2017

Porc Health Manag

View full text Add to dashboard Cite

BackgroundRespiratory diseases impair the health and welfare of growing pigs and impacts farmers’ gains worldwide. Their control through a preventative medical approach has to be tailored according to the pathogens identified at farm level. In the Netherlands, several studies have emphasized the prominent role of Mycoplasma hyopneumoniae, Porcine Circovirus type 2 and Porcine Reproductive and Respiratory Syndrome Virus in such respiratory conditions. Further to the arrival on the Dutch market of the first commercially available bivalent vaccine against PCV2 and M. hyopneumoniae, Porcilis® PCV M. Hyo, a trial was designed to evaluate its safety and efficacy under local field conditions.Material and methodsIn a conventional farrow-to-finish 170-sow farm with a history of respiratory diseases and demonstrated circulation of both M. hyopneumoniae and PCV2, 812 piglets were randomised and included at weaning in either of the three following groups: PCVM (vaccinated with Porcilis® PCV M. Hyo), FLEX (vaccinated with CircoFLEX® and MycoFLEX®) or NC (negative control, injected with placebo). Piglets were vaccinated at 3 weeks of age (day 0) and a subset was bled and weighed at regular intervals up to slaughter. Lung slaughter checks were only performed on 64% of the pigs included on day 0.Results and implicationNo side effect of injection was observed in any of the three groups. Average daily weight gain was improved in both vaccinated groups as compared to the NC group, over the finishing period as well as from wean-to-finish. The PCVM group had a significantly lower PCV2 viremia area under the curve than the two other groups, and a significant reduction in the severity of the pneumonia-like lesions was observed at slaughter in the pigs of the PCVM group. A conservative estimate of the economic benefit of that vaccine was 2.84 € per finisher. This trial confirms that the vaccine is efficacious against the health and growth effects of PCV2 and M. hyopneumoniae, of practical advantage (single injection of a bivalent product) and well tolerated.

show abstract

“…As multiple pathogens are involved in PRDC on many farms, vaccination against several pathogens within PRDC should be considered. Combined vaccines, especially M. hyopneumoniae and PCV-2 [6,[30][31] or PRRSV [32], have recently been developed. However, these combined dual vaccines can only be administered from 21 days of age [2].…”

Section: Introductionmentioning

confidence: 99%

Convenience and economic benefit of early one-shot Mycoplasma hyopneumoniae vaccination at 3 days of age in a commercial sow farm

Vangroenweghe¹

2021

J Vaccines Immunol

View full text Add to dashboard Cite

Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary pathogen of enzootic pneumonia, a chronic respiratory disease in pigs. Vaccination of piglets to protect against M. hyopneumoniae can be performed at several ages, depending on product label specifi cations. Early intervention in the fi rst week of life may have advantages, since piglets can already become infected with M. hyopneumoniae during the suckling period, resulting in a signifi cant percentage of M. hyopneumoniaepositive piglets around weaning. The current study compared convenience and economic benefi ts of M. hyopneumoniae vaccination in piglets of 3, 7 and 14 days of age. Duration of piglet vaccination at 3 days of age was signifi cantly (P < 0.05) shorter (2.64 ± 0.08 seconds) as compared to 7 days of age (4.90 ± 0.18 seconds) and 14 days of age (6.04 ± 0.22 seconds). Economic calculation in a 1000-sow unit, using a vaccination convenience calculator, demonstrated that although the total number of piglets vaccinated is lower (-443 and -838 at 7 and 14 days of age, respectively) at a later vaccination age, the related increase in vaccine cost in the early vaccination group (Group 1) was largely compensated by the decrease in cost of overall vaccination time (€ 1,115.61 and € 1,461.00 lower at 3 days of age as compared to 7 and 14 days of age, respectively). In conclusion, M. hyopneumoniae vaccination at 3 days of age has several advantages over later vaccination at 7 or 14 days of age. Besides the benefi ts in convenience of piglet handling at that age, we could also demonstrate economic benefi ts of early M. hyopneumoniae vaccination.

show abstract

Efficacy and safety of a combined Porcine Circovirus and Mycoplasma hyopneumoniae vaccine in finishing pigs

Cited by 12 publications

References 15 publications

Field evaluation of a ready-to-use combined Porcine circovirus type 2 and Mycoplasma hyopneumoniae vaccine in Denmark – a historical comparison of productivity parameters in 20 nursery and 23 finishing herds

Field evaluation of a ready-to-use combined Porcine circovirus type 2 and Mycoplasma hyopneumoniae vaccine in Denmark – a historical comparison of productivity parameters in 20 nursery and 23 finishing herds

A field efficacy and safety trial in the Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use porcine circovirus type 2 and Mycoplasma hyopneumoniae combined vaccine

Convenience and economic benefit of early one-shot Mycoplasma hyopneumoniae vaccination at 3 days of age in a commercial sow farm

Contact Info

Product

Resources

About